Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
Satoshi Morita(Kyoto University), Toshihiro Nukiwa(Tohoku University), Noriko Yanagitani(The Cancer Institute Hospital), Kenji Sugio(University of Occupational and Environmental Health Japan), Kunihiko Kobayashi(Saitama International Medical Center), Akira Inoue(Tohoku University Hospital), Noriaki Sunaga(Gunma University), Kosei Yasumoto(University of Occupational and Environmental Health Japan), Hajime Asahina(Hokkaido University), Isamu Okamoto(Kyushu University), Tetsuya Mitsudomi(Kindai University), Toyoaki Hida(Aichi Cancer Center), Tomonori Hirashima(Osaka Prefectural Medical Center), Masahiro Fukuoka(National Institute of Standards and Technology), Kimihide Yoshida(Aichi Cancer Center), Koichi Yamazaki(Hokkaido University Hospital), Koichi Hagiwara(Jichi Medical University)
Cited by 189
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k